Pebody, R.G. and Andrews, Nick and Fleming, D.M. and McMenamin, J. and Cottrell, S. and Smyth, B. and Durnall, H. and Robertson, Chris and Carman, W. and Ellis, J. and Sebastian-Pillai, P. and Zambon, Maria and Hearns, C. and Moore, C. and Thomas, D.R. and Watson, J.M. (2012) Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiology and Infection. pp. 1-11. ISSN 0950-2688 (In Press)Full text not available in this repository. (Request a copy from the Strathclyde author)
An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specific adjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI x6 to 51) overall and 72% (95% CI 15–91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.
|Keywords:||Influenza, vaccine-preventable diseases, influenza vaccines, age-specific, vaccine effectiveness , pandemic|
|Department:||Faculty of Science > Mathematics and Statistics|
|Depositing user:||Pure Administrator|
|Date Deposited:||26 Sep 2012 16:24|
|Last modified:||26 Sep 2012 16:24|
Actions (login required)